Rocket Pharmaceuticals Presents Promising Preliminary Results from Phase 1 Trial of Commercial-Grade RP-L102 “Process B” for Fanconi Anemia at 61st American Society of Hematology Annual Meeting

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/19/2026

1. SPY
2. XENE
3. NUE
4. HUBS
5. RTB
6. ONON
7. AAPL
8. TRMD
9. ACN
10. AZN

Go back to Rocket Pharmaceuticals Presents Promising Preliminary Results from Phase 1 Trial of Commercial-Grade RP-L102 “Process B” for Fanconi Anemia at 61st American Society of Hematology Annual Meeting
(NASDAQ: RCKT) Delayed: 3.37 -0.13 (3.71%)
Previous Close $3.50    52 Week High $ 
Open $3.47    52 Week Low $ 
Day High $3.56    P/E N/A 
Day Low $3.35    EPS $ 
Volume 1,598,193